Importantly, losing PHB expression significantly sensitized tumors to IR treatment (Fig. 5a, c) and conferred the longest survival extension among all experimental groups (Fig. 5b, d), highlighting targeting PHB as a therapeutic index for GBM combination therapy. This evidence concerns the gene PHB1 and glioblastoma.